If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What information is available about switching to Mounjaro™ (tirzepatide) for the treatment of type 2 diabetes from a glucagon-like peptide-1 (GLP-1) receptor agonist?
There are currently no data on the effects of switching between tirzepatide and a GLP-1 receptor agonist. The ongoing SURPASS-SWITCH and SURPASS-SWITCH-2 trials evaluate the safety and efficacy of tirzepatide after switching from a GLP-1 receptor agonist.
See important safety information, including boxed warning, in the attached prescribing information.
Prescribing Information Related to Dosing
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
The recommended starting dose of tirzepatide is 2.5 mg once weekly. After 4 weeks, increase the dose to 5 mg once weekly. If needed, dose increases can be made in 2.5 mg increments after a minimum of 4 weeks on the current dose. The maximum dose of tirzepatide is 15 mg once weekly.1
Switching From GLP-1 Receptor Agonist
Eli Lilly and Company currently has no data on the effects of switching between tirzepatide and a GLP-1 receptor agonist.2,3
Switching from a GLP-1 receptor agonist to tirzepatide is being evaluated in 2 ongoing phase 4 studies in adult patients with T2D including
Overview of SURPASS-SWITCH and SURPASS-SWITCH-2 Clinical Trial Designs presents an overview of the SURPASS-SWITCH and SURPASS-SWITCH-2 clinical trial designs.2,3
|
SURPASS-SWITCH2 |
SURPASS-SWITCH-23 |
Design |
Phase 4, randomized, open-label, active-controlled study evaluating the safety and efficacy of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D |
Phase 4, open-label, single-arm study evaluating glycemic control in adults with T2D switching from GLP-1 RA to tirzepatide |
Primary outcome |
Change from baseline in HbA1c at week 40 |
Change from baseline in HbA1c at week 12 |
Estimated enrollment |
250 participants |
150 participants |
Key inclusion criteria |
|
|
Treatment arm |
Participants will
|
Participants will receive tirzepatide SC |
Abbreviations: BMI = body mass index; GLP-1 RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated hemoglobin; OAM = oral antihyperglycemic medication; SC = subcutaneous; SGLT-2i = sodium-glucose cotransporter-2 inhibitor; T2D = type 2 diabetes.
aThe OAM may include metformin, SGLT-2i, and/or sulfonylurea.
bThe OAM may include metformin, SGLT-2i, thiazolidinediones, or α-glucosidase inhibitors.
Transition Considerations
Eli Lilly and Company cannot provide treatment recommendations for switching adults with T2D from a GLP-1 receptor agonist to tirzepatide. Please refer to the prescribing information for approved starting dose of tirzepatide.
Physicians should follow their clinical judgment, considering the patient’s glycemic response and needs, when deciding how to transition from a GLP-1 receptor agonist to tirzepatide.4
When transitioning a patient from a GLP-1 receptor agonist to tirzepatide, the prescribing information of tirzepatide and the applicable GLP-1 receptor agonist and pharmacokinetic/pharmacodynamic profiles should be considered including
- dosing and administration
- safety profile
- onset of action
- duration of action
- half-life
- time to steady state, and
- missed dose information.4
Enclosed Prescribing Information
References
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2A study of tirzepatide (LY3298176) in adult participants with type 2 diabetes switching from dulaglutide (SURPASS-SWITCH). ClinicalTrials.gov identifier: NCT05564039. Updated October 3, 2022. Accessed October 6, 2022. https://clinicaltrials.gov/ct2/show/NCT05564039
3A study of tirzepatide (LY3298176) in adults with type 2 diabetes switching from a GLP-1 RA (SURPASS-SWITCH-2). ClinicalTrials.gov identifier: NCT05706506. Updated February 8, 2023. Accessed February 8, 2023. https://www.clinicaltrials.gov/ct2/show/NCT05706506
4Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: February 07, 2023